title: Q&A: Suzanne Topalian on immune therapies.
abstract: Suzanne Topalian, MD, professor of surgery and oncology and director of the melanoma program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, MD, discusses progress with drugs that inhibit immune-checkpoint receptors and ligands, including PD-1 and PD-L1 inhibitors.
authors.forename: Suzanne
authors.initials: S
authors.lastname: Topalian
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal